VITROS® B•R•A•H•M•S PCT (Procalcitonin)

VITROS® B•R•A•H•M•S PCT (Procalcitonin)

VITROS<sup>®</sup> B•R•A•H•M•S PCT (Procalcitonin)

The power of B•R•A•H•M•S with the difference that only VITROS® can deliver

B•R•A•H•M•S PCT is the best biomarker for early bacterial Sepsis. 

Sepsis is a life threatening condition where the body overreacts to an infection. It affects more than 30 million people with 6 million deaths around the world each year. Identifying and treating the condition as early as possible has been shown to increase the likelihood of survival.  

Sales Support



Request sales information  

Confidence in decisions for Clinicians 

  • Early diagnosis of severe bacterial infections and sepsis1,2
  • Therapeutic guidance for starting and safely stopping antibiotic treatment3,4
  • Excellent analytical correlation and clinical concordance to B•R•A•H•M•S method


1Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6, and interlukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.

2Brunkhorst FM, Wegscheider K, Forycki ZF, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 26:148-152; 2000.

3Branche A, Neeser O, Müller B et al. Procalcitonin to guide antibiotic decision making. Curr Opin Infect Dis. 2019;32(2):130-135.

4Schuetz P, Bolliger R, Merker M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Rev Anti Infect Ther.2018;16(7):555-564.


VITROS® B•R•A•H•M•S PCT (Procalcitonin)

Trust in Results for Laboratories

© Ortho Clinical Diagnostics 2019. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. The availability of the products is subject to compliance with the regulatory requirements of each market.